H.C. Wainwright downgraded Sensei Biotherapeutics (SNSE) to Neutral from Buy without a price target The company this morning announced plans to discontinue development of solnerstotug and initiate a review of strategic alternatives, the analyst tells investors in a research note. The firm moves the sidelines pending future clinical or business development updates. H.C. Wainwright is “disappointed” by solnerstotug being shelved.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNSE:
- Sensei Biotherapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Sensei Biotherapeutics Inc trading resumes
- Sensei Biotherapeutics Discontinues Solnerstotug Development
- Sensei initiates strategic review, implements workforce reduction
- Sensei will not initiate new clinical study for solnerstotug